Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK–signal transducers and activators of transcription pathway, where cytokine receptor signaling takes place. These molecules play a foundational role in...

Full description

Bibliographic Details
Main Authors: Novin Nezamololama, Keira Fieldhouse, Kristy Metzger, Melinda Gooderham
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-11-01
Series:Drugs in Context
Subjects:
abrocitinib
atopic dermatitis
baricitinib
eczema
jak1
jak2
jak inhibitors
upadacitinib
Online Access:https://www.drugsincontext.com/emerging-systemic-jak-inhibitors-in-the-treatment-of-atopic-dermatitis:-a-review-of-abrocitinib,-baricitinib,-and-upadacitinib

Internet

https://www.drugsincontext.com/emerging-systemic-jak-inhibitors-in-the-treatment-of-atopic-dermatitis:-a-review-of-abrocitinib,-baricitinib,-and-upadacitinib

Similar Items